Juan Fueyo-Margareto

MD Anderson
Houston, Texas, United States

Dr. Fueyo is professor of Neuro-Oncology - Research and director of Neuro-Oncology Experimental Research at The University of Texas MD Anderson Cancer Center. He holds a dual appointment as a faculty member in the MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. Dr. Fueyo completed his medical degree and a residency in Neurology at the Autonomous University of Barcelona, Spain. After completing a fellowship in Experimental Neuro-Oncology at MD Anderson, he was promoted to a faculty position.
As principal investigator of studies funded by the NIH, the Department of Defense, the Cancer Prevention and Research Institute of Texas, and philantropic support, Dr. Fueyo is developing novel virotherapy strategies for fighting gliomas. He also is a leader of the prestigious NIH Specialized Program of Research Excellence (SPORE) in brain cancer at his institution. The committed decade-long research of Dr. Fueyo's laboratory led to their engineering of the oncolytic adenovirus Delta-24, which is showing great promise as a potential therapy for patients with glioblastoma, in collaborative work with Drs. Lang and Alonso.
The Delta-24 research team was recognized by MD Anderson through the Waun Ki Hong Award for Excellence in Team Science. In addition, Dr. Fueyo received the Peter A. Steck Memorial Award presented by the Pediatric Brain Tumor Foundation. In 2018, he was included in the Spanish Selection of Science by the Spanish National Research Council. He has been elected Fellow of the American Academy of Neurology and Fellow of the American Association for the Advancement of Science. Dr. Fueyo serves on many scientific sections of NIH, DOD, and several national and international scientific meetings. He has published approximately 300 scholar works. Recently, his studies in virotherapy, performed in collaboration with Dr. Gomez-Manzano, has been showcased by the NCI in Commemoration of its 50th Anniversary.